Raydiant Oximetry Names Michael Nagel to Lead the Company into its Device Commercialization Stage as CEO
SAN RAMON, CA, UNITED STATES, September 16, 2025 /EINPresswire.com/ — Raydiant Oximetry, Inc., a clinical-stage medical device company developing fetal monitoring innovations using advanced biophotonics and machine learning to improve outcomes during childbirth, today announced the appointment of Michael Nagel as Chief Executive Officer.
With more than 35 years of experience leading high-growth, innovative healthcare companies, Nagel joins Raydiant from Vomaris Innovations, a bioelectric wound care company, where he served as CEO and led its recent growth and acquisition by global orthopedic leader Arthrex. He has held senior commercial positions at Neomend, Incisive Surgical, and Vascular Solutions and serves on the boards of EndoShunt and VenoStent.
